TGFB1 and Hepatic fibrosis: As TGF-β1 has been considered as the key cytokine in the activation of HSCs, multiple small molecules or antibodies that target TGF-β1 have potential value in prevention and treatment of hepatic fibrosis (Fagone et al., 2016).